Julie Jordan
Equibles does not estimate personal net worth.
Get an email with a short summary when Neurogene Inc. publishes a filing, an earnings call transcript or a press release.
Get NGNE alertsAbout Julie Jordan
The proxy statement of Neurogene Inc. reports total compensation of $1,472,307 for Julie Jordan in fiscal 2025, including a base salary of $496,800. Disclosed compensation is on record for 2 fiscal years. Neurogene Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Neurogene Inc. includes David J. Main (CEO), Donna M. Cochener (CEO), Rachel McMinn (CEO, Chairman and Board Member) and 7 others.
Affiliation history
-
Neurogene Inc. (NGNE)
Proxy statement
CurrentStart not stated–present
Last confirmed April 16, 2026
-
Q32 Bio Inc. (QTTB)
Proxy statement
Start not stated–2023-04-28
Last confirmed by a filing; no departure on record
Company network
Leadership on record at Neurogene Inc.
- David J. Main CEO
- Donna M. Cochener CEO
- Rachel McMinn CEO, Chairman, Board Member
- Christine Mikail CFO, Board Member
- Christine Mikail Cvijic CFO
- Jonathan Drachman CFO
- Robert Ho CFO
- Sean Smith CFO, Chief Accounting Officer
- Donna Cochener General Counsel
- Cory Freedland Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Neurogene Inc. (NGNE) | Chief Medical Officer | $496,800 | $1,472,307 |
| 2024 | Neurogene Inc. (NGNE) | Chief Medical Officer | $460,000 | $2,460,036 |
Recent activity
No call appearances or filed executive changes recorded yet.